Hazama Yukiko, Moriya Takuya, Sugihara Mika, Sano Rikiya, Shiota Mitsuru, Nakamura Takafumi, Shimoya Koichiro
the Departments of Gynecologic Oncology (R.S., M.S.) Obstetrics and Gynecology (Y.H., M.S, T.N., K.S.) Pathology (T.M.), Kawasaki Medical School, Kurashiki, Japan.
Int J Gynecol Pathol. 2018 Nov;37(6):516-524. doi: 10.1097/PGP.0000000000000461.
In Japan, the frequency of ovarian clear cell carcinoma (CCC) is twice as high as that in the United States and Europe. Often, patient prognosis with CCC is poor because of chemoresistance. Here, we focus on the cell cycle, which is one of the mechanisms of chemoresistance. To detect the informative markers and improve the strategy of chemotherapy for CCC, we performed immunohistochemical staining of cell cycle-related proteins in ovarian malignant tumors. We detected that each of the 29 samples of CCC and high-grade serous carcinoma (HGSC) were necessary to reveal the significant differences in immunostaining and prognosis. We performed the immunostaining analysis using the antibodies of cell cycle-related proteins such as Ki-67, Cdt1, MCM7, and geminin. The positive rate of Cdt1 in the CCC group was significantly higher than that in the HGSC group (P<0.0001). However, the positive rate of geminin in the HGSC group was significantly higher than that in the CCC group (P<0.0001). The overall survival of CCC patients with high labeling index of Cdt1 was significantly worse than that of CCC patients with low labeling index of Cdt1 (P=0.004). The study results suggested that the cancer cells of CCC and HGSC exist in the G1 phase and S, G2, and M phases, respectively. The differences in cell cycle of CCC might be one of the reasons for chemotherapy resistance. Further investigations are necessary to reveal the usefulness of Cdt1 as a biomarker in CCC.
在日本,卵巢透明细胞癌(CCC)的发病率是美国和欧洲的两倍。通常,由于化疗耐药性,CCC患者的预后较差。在此,我们聚焦于细胞周期,它是化疗耐药机制之一。为了检测相关信息标志物并改进CCC的化疗策略,我们对卵巢恶性肿瘤中的细胞周期相关蛋白进行了免疫组化染色。我们发现,29份CCC和高级别浆液性癌(HGSC)样本中的每一份对于揭示免疫染色和预后的显著差异都是必要的。我们使用细胞周期相关蛋白的抗体,如Ki-67、Cdt1、MCM7和geminin进行免疫染色分析。CCC组中Cdt1的阳性率显著高于HGSC组(P<0.0001)。然而,HGSC组中geminin的阳性率显著高于CCC组(P<0.0001)。Cdt1标记指数高的CCC患者的总生存期显著低于Cdt1标记指数低的CCC患者(P=0.004)。研究结果表明,CCC和HGSC的癌细胞分别处于G1期和S、G2及M期。CCC细胞周期的差异可能是化疗耐药的原因之一。有必要进一步研究以揭示Cdt1作为CCC生物标志物的实用性。